+

WO2005000341A1 - Utilisation de l'hydroperoxyde glutathione peroxydase phospholipide cytosolique afin de reduire la croissance tumorale - Google Patents

Utilisation de l'hydroperoxyde glutathione peroxydase phospholipide cytosolique afin de reduire la croissance tumorale Download PDF

Info

Publication number
WO2005000341A1
WO2005000341A1 PCT/EP2004/051216 EP2004051216W WO2005000341A1 WO 2005000341 A1 WO2005000341 A1 WO 2005000341A1 EP 2004051216 W EP2004051216 W EP 2004051216W WO 2005000341 A1 WO2005000341 A1 WO 2005000341A1
Authority
WO
WIPO (PCT)
Prior art keywords
cphgpx
tumor
cells
cytosolic
cox
Prior art date
Application number
PCT/EP2004/051216
Other languages
English (en)
Inventor
Johan Grooten
Ingeborg Heirman
Original Assignee
Vib Vzw
Universiteit Gent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vib Vzw, Universiteit Gent filed Critical Vib Vzw
Publication of WO2005000341A1 publication Critical patent/WO2005000341A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01012—Phospholipid-hydroperoxide glutathione peroxidase (1.11.1.12)

Definitions

  • the present invention relates to the reduction of tumor growth. More specifically, the present invention relates to the use of cytosolic phospholipid hydroperoxide glutathione peroxidase (cPHGPx) to reduce tumor growth. Moreover, the present invention relates to the detection of mutations in the gene, encoding cPHGPx, to forecast the likelihood to develop cancer and/or to forecast the likelihood to develop metastasis and/or to determine the aggressiveness of the tumor
  • the oxidant - antioxidant balance of a cell regulates to an important extent the different cellular and metabolic functions.
  • a disturbance of the redox state by external and/or internal stimuli may result in a disturbance of cell functions (Finkel, 1998).
  • reactive oxygen intermediates (ROI) are essential for cell proliferation, but at the same time, the cells need defense mechanisms to avoid oxidative stress and to inhibit ROI induced apoptosis (Gottlob etal., 2001). Cells do produce considerable amounts of ROI. Those ROI may cause damage to the DNA both in a direct or in an indirect way - the latter mainly by degradation of lipid hydroperoxydes (ROOH).
  • hypoxia In this hypoxia response, the mitochondria and the production of ROI play an essential role (Chandel et al., 2000). Apart from the induction by HIF-1 ⁇ of genes involved in angiogenesis, hypoxia also induces apoptosis and hence promotes the outgrowth of tumor cells with increased resistance to apoptosis (Piret et al., 2002; Schmaltz et al., 1998). Another important stimulus for ROI production in tumor cells is inflammation.
  • the tumor inducing mechanism of the COX reaction products include the inhibition of apoptosis, the stimulation of angiogenesis, the promotion of metastasis and the stimulation of tumor cell proliferation. Recently, it has been shown that also leukotrienes can stimulate the proliferation of tumor cells and repress apoptosis.
  • PGE 2 prostaglandin E 2
  • a first aspect of the invention is the use of the cPHGPx gene, or a functional fragment thereof, to modulate the onset of tumor formation and/or tumor growth.
  • said tumor is chosen from the group of fibrosarcoma.
  • said tumor is a brain metastasis.
  • said use is an overexpression of the gene, or a functional fragment thereof, and said modulation is a retardation of the onset and/or a reduction in tumor growth.
  • a preferred functional fragment is the coding sequence of the gene.
  • said coding sequence may be placed after a strong inducible or constitutive promoter, to facilitate overexpression of cPHGPx.
  • said coding sequence may be operably linked to a tissue specific promoter, or to a promoter that is induced in tumor cells, such as a hypoxia induced promoter.
  • Vectors and methods for gene therapy are known to the person skilled in the art, and include, but are not limited to ex vivo and in vivo gene therapy, and adenoviral, retroviral and lentiviral vectors.
  • the overexpression of endogenous cPHGPx may be induced by the addition of a compound. Indeed, it is know that several compounds are inducing the cPHGPx gene.
  • the cPHGPx gene is induced by superoxide radicals and/or by singlet oxygen. Therefore, said compounds can be used to induce the cPHGPx gene, as well as compounds that result in superoxide radical formation and/or singlet oxygen formation.
  • WO02078718 describes compositions, methods, apparatuses and systems for singlet oxygen delivery.
  • Said singlet oxygen can be used for the treament of tumors.
  • the singlet oxygen is believed to produce toxic effects on the cells of the tumor through oxidation and/or free radical reactions.
  • Induction of cPHGPx which may occur at lower concentration of singlet oxygen than the induction of the above-mentioned toxic reactions, is not considered.
  • cPHGPx may be induced by the addition of selenium, or by tertiary- butyl hyperoxide. Said induction may be combined with other forms of overexpression of cPHGPx, as described above.
  • cPHGPx protein As overexpression of the cPHGPx gene will result in an increased amount of cPHGPx, another aspect of the invention is the use of cPHGPx protein to delay the onset of tumor formation, and/or to reduce tumor growth.
  • said therapy is an anti-angiogenic therapy.
  • Anti-angiogenic therapy is known to the person skilled in the art, and includes, but is not limited to treatment with Avastin, Vitaxin, Herceptin or TNF.
  • said anti-angiogenic treatment is a TNF treatment.
  • said therapy is the photodynamic therapy.
  • the use of the cPHGPx gene may occur during the cancer treatment, or alternatively it may be phased, by giving first the tumor therapy, followed by induction and/or overexpression of the cPHGPX gene, or delivering the cPHGPx protein to the tumor, or vice versa.
  • said therapy is preferably applied first, followed by the use of the cPHGPx gene according to the invention.
  • Still another aspect of the invention is the use of the PHGPx gene, or a functional fragment thereof, for diagnosis related to cancer and malignancy.
  • said diagnosis is the determination of the likelihood to develop cancer and/or the determination of the likelihood to develop metastasis and/or the determination of the aggressiveness of the tumor.
  • said cancer is chosen from the group of fibrosarcoma. melanoma lymphoma, breast, lung and colon cancer and brain metastases.
  • said cancer is brain metastasis.
  • the diagnosis may be related to the expression level of the cPHGPx gene, which can be tested both on RNA or on protein level, or it may be related to mutations which affect either the expression level of the gene or the activity of the protein.
  • mutations in the gene may affect the tumor development. Said mutations may be affecting the expression of the gene, such as a mutation in the promoter region, or they may affect the activity of the gene, such as a mutation in the coding sequence.
  • a functional fragment of the gene for use in diagnosis is every fragment that gives rise to specific primers, which can be used in, as a non-limiting example, polymerase chain reaction (PCR) or hybridization experiments. Preferably, said fragments are used in small nuclear polymorphism (SNP) analysis. Methods for SNP analysis are known to the person skilled in the art.
  • said diagnosis may be carried out by the use of antibodies against the cPHGPx protein, or against a specific domain of said protein.
  • the expression level can be tested by measuring the protein in a quantitative way, by immunological techniques such as ELISA, or mutations in the protein can be detected by binding or loss of binding of an antibody directed against the domain carrying the mutation.
  • cPHGPx mRNA levels may be measured. Methods to measure mRNA levels are known to the person skilled in the art and include, but are not limited to quantitative PCR and quantitative micro array analysis.
  • Figure 2 Effect of cPHGPx-transfectants on the tumor growth of neo-cells.
  • Figure 4 Expression of the key enzymes of the eicosanoid metabolism and of the receptors of PGE 2 . Expression was measured using Q-PCR with SYBR green. The specificity of the primers was checked by a melting curve.
  • Figure 5 Role of COX-2 in cPHGPx related tumor growth inhibition. The effects of meloxicam on neo tumor growth (A) and of 16.16dmPGE 2 on cPHGPx tumorgrowth (B) were studied. The insert shows the effect of the combination of meloxicam and 16,16dmPGE 2 on neo (A) and on cPHGPx (B) tumor growth. 2 10 5 tumor cells/ mouse were injected subcutaneously. The treatment with meloxicam was done with daily intraperitoneal injection at a concentration of 3mg/kg body weight; treatment with 16,16dmPGE 2 was also by intra peritoneal injections, 3 times a week, using 10 ⁇ g per mouse.
  • FIG. 6 Expression of COX-2 in neo and cPHGPx cells after hypoxia or after hypoxia followed by reoxygenation. RNA was prepared after 6 hours or 16 hours of hypoxia (1% O ), or after hypoxia followed by reoxygenation for 1 hour, at 20% O 2 . COX-2 mRNA expression was quantified with Q-PCR using SYBR green.
  • Figure 7 Role of 5-LOX in L929 induced tumor growth in mice. Effect of the 5-LOX inhibitor zyflo at 60 mg/kg daily on L929 tumor growth on L929 neo and L929 cPHGPx. The treatment was started at day 8 after injection of the L929 cells in the mice.
  • FIG 8 Role of COX-1 in L929 induced tumor growth in mice. Effect of the COX-1 inhibitor piroxicam at 7.5 mg/kg daily on L929 tumor growth on L929 neo and L929 cPHGPx. The treatment was started at day 8 after the injection of the L929 cells in the mice.
  • Figure 9 The influence of hypoxia on the expression of the enzymes involved in the transformation of archidonic acid in prostanoids in L929 cells. Samples were analyzed after 8, 15 and 30 hours of hypoxia.
  • Figure 10 Effect of hypoxia on the level of COX-2 protein in L929 neo and L929 cPHGPx cells. Samples were analyzed after 8, 15 and 30 hours of hypoxia.
  • Figure 11 Effect of hypoxia on the expression level of (A) COX-2, (B) COX-1, (C) PLA2 and (D) 5-LOX in B16BL6 neo and B16BL6 cPHGPx cells.
  • FIG. 12 Effect of mouse TNF ⁇ on the growth of (A) B16BL6, (B) B16BL6 neo and (C) B16BL6 cPHGPx induced tumor growth in mice.
  • the treatment with TNFpc was started 10 days after injection with the B16BL6 cells.
  • the graphs represent the average of 3 mice.
  • Gene as used here includes both the promoter region of the gene as well as the coding sequence. It refers both to the genomic sequence (including possible introns) as well as to the cDNA derived from the spliced messenger, operably linked to a promoter sequence-
  • Coding sequence is a nucleotide sequence, which is transcribed into mRNA and/or translated into a polypeptide when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a translation start codon at the 5'- terminus and a translation stop codon at the 3'-terminus.
  • a coding sequence can include, but is not limited to mRNA, cDNA, recombinant nucleotide sequences or genomic DNA, while introns may be present as well under certain circumstances.
  • Operably linked refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner.
  • a promoter sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the promoter sequence.
  • Nucleotide sequence refers to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. This term refers only to the primary structure of the molecule. Thus, this term includes double- and single-stranded DNA, and RNA. It also includes known types of modifications, for example, methylation, "caps" substitution of one or more of the naturally occurring nucleotides with an analog.
  • Promoter region of a gene as used here refers to a functional DNA sequence unit that, when operably linked to a coding sequence and possibly placed in the appropriate inducing conditions, is sufficient to promote transcription of said coding sequence.
  • protein and polypeptide as used in this application are interchangeable.
  • Polypeptide refers to a polymer of amino acids and does not refer to a specific length of the molecule. This term also includes post-translational modifications of the polypeptide, such as glycosylation, phosphorylation and acetylation
  • Compound means any chemical of biological compound, including simple or complex organic and inorganic molecules, peptides, peptido-mimetics, proteins, antibodies, carbohydrates, nucleic acids or derivatives thereof.
  • Tumor stimulating factor or tumor promoting factor as used here may be any compound that is obtained by the action of COX and LOX enzymes.
  • Preferably said compounds are cytosolic lipidhydroperoxides.
  • the aggressiveness of the tumor as used here relates to the growth rate of the tumor tissue, faster growing tumors being considered as more aggressive.
  • L929 cPHGPx L929 fibrosarcoma cells that overexpress cPHGPx * Transfection: DNA-calciumphosphate co-precipitation with DNA-mixture consisting of carrier DNA (pSV23s), selectionplasmid (pSV2_neo) and pCAGGS_cPHGPx * cPHGPx in pCAGGS-vector under control of the ⁇ -actin/ ⁇ -globin hybrid promotor
  • L929 fibrosarcoma cells that are transfected only with the selectionplasmid * Transfection: DNA-calciumphosphate co-precipitation withDNA-mixture consisting of carrier DNA (pSV23s) and selectionplasmid (pSV2_neo)
  • B16BL6 cPHGPx B16BL6 melanoma cells that overexpress cPHGPx * Transfection: co-transfection using lipofectamine with DNA-mixture consisting of selectionplasmid (pSV2_neo) and pCAGGS_cPHGPx * cPHGPx in pCAGGS-vector under control of the ⁇ -actin/ ⁇ -globin hybrid promotor
  • B16BL6 neo B16BL6 melanoma cells that are only transfected with the selection plasmid * Transfection: transfection using lipofectamine with only using selectionplasmid (pSV2_ eo) ce strains used
  • mice immunodeficient mice (no T-cells) used for tumor experiments with L929 cells
  • mice immunocompetent mice used for tumor experiments with B16BL6 cells Tumor experiments with L929 orB16BL6 cells.
  • - tumor cells are grown to subconfluency - cells are dislodged with EDTA-Trypsine and washed 3 times with LPS-free PBS - cells are resuspended at 1.10 6 cells/ml (L929) or 25000 cells/ml (B16BL6) in LPS-free PBS - 200 ⁇ l cell suspension ( ⁇ 2.10 5 L929 cells or 5000 B16BL6 cells) is injected subcutaneously in mice - tumor diameters are measured 3 times / week
  • COX- and LOX-inhibitors Specific inhibitors of the COX and LOX enzymes that are expressed during tumor growth were used to study the role of these enzymes in L929 or B16BL6 tumor growth and their role as cPHGPx-target. Administration to the mice bearing tumors happens intraperitonially or subcutaneously. These inhibitors were used separately or in combination.
  • COX- and LOX-products The involvement of COX- and LOX-products in L929 and B16BL6 tumor growth was examined through administration of these products to mice injected with the tumor cells.
  • TNF treatment C57B1/6 mice were injected subcutaneously with 6.10 5 tumor cells (B16L6, B16L6 neo or B16L6 cPHGPx). 10 days after injection, TNF ⁇ treatment was started by applying paralesionally a daily dose of 1 ⁇ g/mice. The treatment was continued for 10 days. The dose applied is about 7 times lower than the dose needed to obtain a clear tumor regression.
  • B16BL6 melanoma model Performed with B16BL6 melanoma model as these tumor cells are very well suited for study of metastasis because of their pigmentation with melanin. 2 strategies are followed comparing B16BL6 neo with B16BL6 cPHGPx: 1. injection of tumor cells in the rear limb of mice and amputation of this limb when a primary tumor is formed.
  • Genomic DNA-isolation - performed on tumors excised at mean diameters of 4mm and 10mm - genomic DNA-isolation is performed using Generation capture column DNA isolation Kit - Gentra Systems and following manufacturer's instructions
  • RNA-isolation performed using either TRIzol (Invitrogen) or RNeasy-kit (Qiagen) - DNase-treatment: with DNase I (Qiagen) cDNA-svnthesis - reverse transcriptase enzyme used is Superscript II RNase H " (Invitrogen) real-time PCR - Sybr Green based real-time PCR (Eurogentec)
  • hypoxia 1% O 2 - 5% CO 2 - 94% N 2 .
  • Medium of the cells is overnight pre-incubated in these conditions and at the start of the experiment the medium of the cells is replaced with the pre-incubated medium.
  • Normoxia is defined as 20% O 2 - 5%CO 2 - 75% N 2
  • Specific primers are designed to amplify specific regions of the genomic DNA. Thereafter, this PCR-product is sequenced.
  • the inhibitory effect may then be explained either by the fact that the cPHGPx transfectants do change the microenvironment of the tumor, which results in a tumor inhibition, or by the fact that said transfectants are unable to synthesize certain tumor stimulating factors-
  • neo-cells (transfected with the selection plasmid only) and cPHGPx cells were mixed in vitro, using different amounts of cPHGPx cells, and the tumor growth was evaluated after inoculation of the cells or the cell mixtures in nu/nu mice. The results are presented in figure 2.
  • cPGHPx cells has no influence on the tumor growth of the neo-cells, which proves that the inhibition by the overexpression of cPHGPx is not due to a change in microenvironment of the tumor, but rather to the absence of one or more tumor stimulating factors in the cPHGPx- transfectants.
  • overexpression of cytosolic CuZn superoxide dismutase or cytosolic catalase strongly suggested that O 2 " nor H 2 O 2 had a direct influence on tumor growth.
  • the tumor stimulating factor cannot be produced by the lipid peroxidation chain reaction, but should be formed enzymatically during the tumor growth, by the enzymatic action of COX and LOX.
  • neo-cells were mixed at a total amount of 2 10 5 cells. This is the maximal amount where there is still a dose response of cells injected on tumor growth. From figure 3, it can be deduced that the growth of the mixed population is close to that of the neo-cells alone, and far higher than that of the cPHGPx cells alone. These results indicate that the neo-cells indeed do have a tumor growth promoting effect on the cPHGPx cells, by releasing a tumor growth promoting factor. The results were confirmed by analyzing the composition of the tumors at genomic DNA level, in tumors with a diameter of 4 and 10 mm.
  • cPHGPx was quantified using Q- PCR (SYBR Green) and expressed as a ration on m ⁇ -actin (Table 1).
  • SYBR Green Q- PCR
  • Table 1 m ⁇ -actin
  • cells were mixed as in vitro culture and measured. In neo-cells, no cPHGPx can be detected, proving the specificity of the primers used.
  • the in vitro results show an intermediate value for the ratio, compared with the results on pure neo- and pure cPHGPx-cells, proving the validity of the approach. Both in tumors of 4mm and 10mm induced by the mixed population, cPHGPx can be detected, be it at a lower ration in the bigger tumors.
  • Table 1 composition of the tumors, induced by a constant number of cells, either by pure neo- cells, pure cPHGPx cells, or a mixture of both.
  • the mixture contained neo-cells and cPHGPx cells in a ratio 1/1.
  • the results are expressed as a ratio of cPHGPx on m ⁇ -actin, as determined by Q-PCR on genomic DNA.
  • NR not relevant
  • Example 2 Expression of the enzymes of the eicanosoid metabolism Overexpression of CuZnsuperoxide dismutase or catalase did not reduce the tumor growth, indicating that the tumor promoting factors were not originating from the lipid peroxidation chain reaction, but were formed enzymatically by the activity of COX and LOX.
  • Example 3 Role of COX-2 in cPHGPx induced inhibition of tumor growth.
  • COX-2 is about 10 times more sensitive to cPHGPx inhibition than COX-1 or 5-LOX (Huang et al., 1999). Therefore, the possible role of COX-2 as target for the cPHGPx induced inhibition of tumor growth was studied in detail.
  • the COX-2 specific inhibitor meloxicam was added to see if the tumor growth is inhibited in a similar way as by cPHGPx overexpression.
  • the PGE 2 analog 16,16-dimethyI-PGE 2 was added to check if the effect of cPHGPx overexpression on tumor growth could be neutralized.
  • Treatment with 16.16-dimethyl-PGE 2 results in a faster onset of the tumor formation by injection with cPHGPx cells, and makes the tumor detectable at about the same time as for the control neo-cells (figure 5B).
  • 16.16-dimethyl-PGE 2 is applied together with meloxicam, the effect is neutralized.
  • the results indicate that COX-2 is indeed a target of cPHGPx.
  • inhibition with meloxicam proofs to be less efficient than inhibition using cPHGPx overexpression, indicating that cPHGPx is working on several targets simultaneaously.
  • Example 4 Hypoxia as stimulus for COX-2 induction during tumor growth Hypoxia is an important stimulus for COX induction (Schmedtje et al., 1997). This is also seen in the L929 neo-cells ( Figure 6). Hypoxia (1% O 2 ) gave a clear COX-2 induction; in neo-cells, treated with hypoxia followed by reoxygenation till 20% 0 2 , the effect is even slightly more pronounced. However, in the cPHGPx overexpressing cells, no COX-2 induction can be noticed, neither after hypoxia, nor after hypoxia followed by reoxygenation.
  • hypoxia may occur starting from a tumor volume as small as 1 mm 3
  • the COX-2 repression and the resulting decrease in angiogenesis and increased apoptosis may be an important factor in the slower tumor formation by cPHGPx overexpression.
  • COX-1 is the third enzyme of the eicosanoid metabolism which is expressed in L929 cells
  • the role of COX-1 inhibition by cPHGPx in tumor inhibition was also studied, using piroxicam as inhibitor-
  • the results are summarized in Figure 8.
  • the inhibitory effect of peroxicam on L929 neo tumor growth inhibition is limited and far less important than that of meloxicam and xyflo, thus indicating that although COX-1 is a target of cPHGPx the contribution of COX-1 to promotion of tumor growth is far less important than that of COX-2 and 5-LOX.
  • Example 6 Effect of hypoxia on COX-1, COX-2, PLA2 and 5-LOX expression in L929 neo and B16BL6 neo cells, compared with L929 cPHGPx and B16BL6 cPHGPx cells
  • L929 cells were placed in hypoxia conditions, and the effect on RNA and protein levels was studied. Samples were analyzed after 8, 15 and 30 hours of hypoxia. As shown in Figure 9, there is a clear induction of COX-2 by hypoxia in L929 neo cells, whereas no induction is seen in L929 cPHGPx while on the contrary, COX-1 is only induced in L929 cPHGPx cells. There is no significant difference between the induction of PLA2 under normoxia and hypoxia. It is remarkable, however, that the expression of PLA2 in L929 cPHGPx is significantly lower than for L929 neo.
  • COX-2 is hardly detectable in L929 cPHGPx cells, even in hypoxia.
  • COX-2 protein was clearly detectable in L929 neo cells following culture under hypoxia conditions. Similar experiments were carried out on B16BL6 cells. In this case, the induction in B16BL6 neo cells of COX-2 by hypoxia was apparent only after 15 hours, similar to L929 cPHGPx. B16BL6 cPHGPx cells failed to upregulate COX-2 upon hypoxia.
  • COX-1 has a similar evolution as COX-2, but in contrast to the L929 cells, B16BL6 cPHGPx cells show a low induction by hypoxia compared with the neo control. The repression of PLA2 in B16BL6 cPHGPx cells is even more pronounced than for their L929 counterpart.
  • 5-LOX shows a similar evolution as COX-1 and COX-2, with a maximal induction after 15 hours of hypoxia. Again this induction is suppressed in B16BL6 cPHGPx cells (Figure 11).
  • Example 7 Effect of cPHGPx on the efficacy of TNF ⁇ tumor therapy
  • TNF ⁇ has a known anti-tumor activity by its anti-angiogenic activity on the tumor vasculature. However, it exerts also a tumor promoting effect due to its COX-2 inducing effect. This induction results in the production of tumor-promoting prostanoids. Therefore, high doses of TNF ⁇ are needed to obtain the desired anti-tumoral effect.
  • inhibition of the COX-2 induction by cPHGPx results in a clear tumor reduction at lower dosage of TNF ⁇ .
  • Example 8 Improved efficacy of photodynamic therapy by combination with cPHGPx
  • PDT photodynamic therapy
  • a photosensitizer such as hypericine, which is preferentially taken up and retained by tumor cells, is exited by visible light.
  • hypericine When returning to its ground state, hypericine generates superoxide radicals and/or singlet oxygen that promote tumor cell destruction (Agostinis ef al., 2002).
  • PDT is an accepted anticancer modality, its application is limited to small, superficial tumors. The induction of survival mechanisms under suboptimal light stimulation is responsible for this limitation and involves the upregulation of COX-2 expression and PGE 2 production.
  • cPHGPx-overexpression inhibits COX-2 activity as well as the induction of COX-2 in response to hypoxia, cPHGPx-overexpression suppresses this defense mechanism.
  • cPHGPx clearly suppresses COX-2 induction by PDT performed under suboptimal light stimulation. Combining cPHGPx with PDT extends the applicability of PDT to larger tumors and to a much wider range of tumor types.
  • Example 9 cPHGPx single-nucleotide polymorphism (SNP) analysis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention se rapporte à la réduction d'une croissance tumorale, et plus particulièrement, à l'utilisation d'une hydroperoxyde glutathione peroxydase cytosolique phospholipide (cPHGPx) afin de réduire la croissance tumorale. Par ailleurs, l'invention porte sur la détection de mutations dans le gène, codant cPHGPx afin de prévoir la probabilité de développer un cancer et/ou de prévoir la probabilité de développer une métastase et/ou de déterminer l'agressivité de la tumeur.
PCT/EP2004/051216 2003-06-25 2004-06-23 Utilisation de l'hydroperoxyde glutathione peroxydase phospholipide cytosolique afin de reduire la croissance tumorale WO2005000341A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03101891.4 2003-06-25
EP03101891 2003-06-25

Publications (1)

Publication Number Publication Date
WO2005000341A1 true WO2005000341A1 (fr) 2005-01-06

Family

ID=33547754

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/051216 WO2005000341A1 (fr) 2003-06-25 2004-06-23 Utilisation de l'hydroperoxyde glutathione peroxydase phospholipide cytosolique afin de reduire la croissance tumorale

Country Status (1)

Country Link
WO (1) WO2005000341A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015196245A1 (fr) * 2014-06-25 2015-12-30 Adelaide Research & Innovation Pty Ltd Modulation de l'ostéogenèse et/ou de l'angiogenèse par modulation de la fonctionnalité peroxydase

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0750911A1 (fr) * 1995-06-07 1997-01-02 Life Science Labs, Inc. Composition pour la réduction de la fréquence des cancers et pour l'allongement de la durée de vie
US5632982A (en) * 1994-06-07 1997-05-27 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic enhancement of TNF with copper
US20020106348A1 (en) * 2000-07-12 2002-08-08 Peng Huang Cancer therapeutics involving the administration of 2-methoxyestradiol and an agent that increases intracellular superoxide anion
WO2002072626A2 (fr) * 2001-02-15 2002-09-19 Hahn-Meitner-Institut Berlin Gmbh Nouvelle forme de la proteine phgpx en tant que marqueur dans le diagnostic de la sterilite masculine
WO2002078718A2 (fr) * 2001-01-22 2002-10-10 Howes Randolph M Compositions, methodes, appareils et systemes pour administration d'oxygene singlet

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5632982A (en) * 1994-06-07 1997-05-27 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic enhancement of TNF with copper
EP0750911A1 (fr) * 1995-06-07 1997-01-02 Life Science Labs, Inc. Composition pour la réduction de la fréquence des cancers et pour l'allongement de la durée de vie
US20020106348A1 (en) * 2000-07-12 2002-08-08 Peng Huang Cancer therapeutics involving the administration of 2-methoxyestradiol and an agent that increases intracellular superoxide anion
WO2002078718A2 (fr) * 2001-01-22 2002-10-10 Howes Randolph M Compositions, methodes, appareils et systemes pour administration d'oxygene singlet
WO2002072626A2 (fr) * 2001-02-15 2002-09-19 Hahn-Meitner-Institut Berlin Gmbh Nouvelle forme de la proteine phgpx en tant que marqueur dans le diagnostic de la sterilite masculine

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
HOLBEN D H ET AL: "The diverse role of selenium within selenoproteins: a review.", JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION. UNITED STATES JUL 1999, vol. 99, no. 7, July 1999 (1999-07-01), pages 836 - 843, XP002263054, ISSN: 0002-8223 *
LIN F ET AL: "SELENOPEROXIDASE-MEDIATED CYTOPROTECTION AGAINST MEROCYANINE 540-SENSITIZED PHOTOPEROXIDATION AND PHOTOKILLING OF LEUKEMIA CELLS", CANCER RESEARCH, vol. 52, no. 19, 1992, pages 5282 - 5290, XP001156229, ISSN: 0008-5472 *
MAIORINO M ET AL: "(47) PHOSPHOLIPID HYDROPEROXIDE GLUTATHIONE PEROXIDASE", METHODS IN ENZYMOLOGY, ACADEMIC PRESS INC, SAN DIEGO, CA, US, vol. 186, 1990, pages 448 - 457, XP000921458, ISSN: 0076-6879 *
SUN Q ET AL: "EFFECT OF SELENIUM ON HUMAN PHOSPHOLIPID HYDROPEROXIDE GLUTATHIONE PEROXIDASE EXPRESSION AND HOST CELL SUSCEPTIBILITY TO LIPID HYDROPEROXIDE-MEDIATED INJURY", BIOCHEMISTRY AND MOLECULAR BIOLOGY INTERNATIONAL, ACADEMIC PRESS, LONDON, GB, vol. 42, no. 5, August 1997 (1997-08-01), pages 957 - 963, XP008014177, ISSN: 1039-9712 *
WANG HONG P ET AL: "Phospholipid hydroperoxide glutathione peroxidase induces a delay in G1 of the cell cycle.", FREE RADICAL RESEARCH, vol. 37, no. 6, June 2003 (2003-06-01), pages 621 - 630, XP009022014, ISSN: 1071-5762 (ISSN print) *
WANG HONG P ET AL: "Phospholipid hydroperoxide glutathione peroxidase protects against singlet oxygen-induced cell damage of photodynamic therapy", FREE RADICAL BIOLOGY AND MEDICINE, vol. 30, no. 8, 15 April 2001 (2001-04-15), pages 825 - 835, XP002263055, ISSN: 0891-5849 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015196245A1 (fr) * 2014-06-25 2015-12-30 Adelaide Research & Innovation Pty Ltd Modulation de l'ostéogenèse et/ou de l'angiogenèse par modulation de la fonctionnalité peroxydase

Similar Documents

Publication Publication Date Title
Ye et al. 3, 3′-Diindolylmethane induces anti-human gastric cancer cells by the miR-30e-ATG5 modulating autophagy
Qin et al. A role for the WWOX gene in prostate cancer
Ma et al. Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma
Pawella et al. Perilipin discerns chronic from acute hepatocellular steatosis
Wang et al. miR-9 and NFATc3 regulate myocardin in cardiac hypertrophy
Choi et al. NFκB and STAT3 synergistically activate the expression of FAT10, a gene counteracting the tumor suppressor p53
KR100681763B1 (ko) 인간 리포칼린 2를 유효성분으로 포함하는 암 전이 억제용약학적 조성물, 이를 이용한 암 전이 억제 방법
Xu et al. The microRNA miR-17 regulates lung FoxA1 expression during lipopolysaccharide-induced acute lung injury
Menna et al. Inhibition of aggressiveness of metastatic mouse mammary carcinoma cells by the β2-chimaerin GAP domain
Liu et al. Sirt6 mediates antioxidative functions by increasing Nrf2 abundance
Witting et al. Helper-dependent adenovirus-mediated short hairpin RNA expression in the liver activates the interferon response
Shao et al. Epigenetic activation of CTGF transcription by high glucose in renal tubular epithelial cells is mediated by myocardin-related transcription factor A
Li et al. Collagen prolyl hydroxylase 3 has a tumor suppressive activity in human lung cancer
CN110665007A (zh) 一种治疗癌症用组合药物及其用途
EP3114233B1 (fr) Procédé de prédiction de la réactivité à un traitement avec un anticorps anti-cd20
Wang et al. linc00174 deteriorates the pathogenesis of diabetic retinopathy via miR-26a-5p/PTEN/Akt signalling cascade-mediated pyroptosis
Reis et al. Experimental animal model and RNA interference: a promising association for bladder cancer research
Zhang et al. Unc-51 like autophagy activating kinase 1 accelerates angiotensin II-induced cardiac hypertrophy through promoting oxidative stress regulated by Nrf-2/HO-1 pathway
WO2005000341A1 (fr) Utilisation de l'hydroperoxyde glutathione peroxydase phospholipide cytosolique afin de reduire la croissance tumorale
Dickson et al. Upstream Stimulatory Factor Is Required for Human Angiotensinogen Expression and Differential Regulation by the A− 20C Polymorphism
JP2007528717A (ja) 結腸直腸癌を診断する方法
Lee et al. Anti-apoptotic role of S100A8 in X-ray irradiated keratinocytes
US20190185852A1 (en) Therapeutically modulating apob and apoai
KR102085260B1 (ko) Ccnd3 또는 pak2 유전자의 발현을 저해하는 암을 치료하기 위한 약학적 조성물
KR101445921B1 (ko) ｍｉＲ-185의 항암적 용도

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载